Completed OBSERVATIONAL NCT05582941

Biomarkers of Cognitive Impairment in Blood Cells (COGNIMARK)

Use of Human Blood Cells for the Identification of Early Biomarkers of Cognitive Damage

Sponsor: Consorcio Centro de Investigación Biomédica en Red (CIBER)

Conditions Dementia Due to Alzheimer's Disease (Disorder) Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions No intervention will be performed.

Updated 6 times since 2022 Last updated: Jul 1, 2025 Started: Apr 1, 2022 Primary completion: May 31, 2023 Completion: May 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Dementia Due to Alzheimer's Disease (Disorder) and Mild Cognitive Impairment Due to Alzheimer's Disease, this trial is completed. The trial is conducted by Consorcio Centro de Investigación Biomédica en Red (CIBER) and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Aug 2025 — Present [monthly]

Completed

Status: Unknown → Completed
Nov 2024 — Aug 2025 [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Mar 2023 — Jul 2024 [monthly]

Recruiting

▶ Show 1 earlier version

Nov 2022 — Mar 2023 [monthly]

Recruiting

First recorded

Apr 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Consorcio Centro de Investigación Biomédica en Red (CIBER)
Fundació d'investigació Sanitària de les Illes Balears
University of the Balearic Islands

Data source: University of the Balearic Islands

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Palma, Mallorca, Spain